Short Bowel Syndrome Market by Treatment Type (Oral Supplementation, Parenteral Nutrition, Pharmacological Therapy), Product Type (Adjunctive Therapies, Enteral Formulas, Pharmacologics), Route Of Administration, Patient Age, Etiology, End Use - Global Fo
Description
The Short Bowel Syndrome Market was valued at USD 1.14 billion in 2024 and is projected to grow to USD 1.22 billion in 2025, with a CAGR of 9.22%, reaching USD 2.31 billion by 2032.
An authoritative overview of clinical burdens, multidisciplinary care demands, and commercial imperatives shaping short bowel syndrome treatment strategies
Short bowel syndrome presents a complex clinical and commercial landscape shaped by heterogeneous patient profiles, intricate nutritional requirements, and rapidly evolving therapeutic pathways. The condition creates sustained needs across medical nutrition, pharmacologic support, and procedural interventions, demanding coordinated care models that integrate specialty clinics, hospital systems, and home care services. Recent advances in pharmacology and surgical techniques are reshaping standards of care, while improvements in outpatient parenteral nutrition and home infusion services are changing how long-term support is delivered.
Clinicians and industry stakeholders face converging pressures: the imperative to improve patient quality of life, reduce catheter-related complications, and optimize nutrient absorption, alongside payer scrutiny and supply chain resilience requirements. Consequently, commercial strategies must balance clinical efficacy, ease of administration, and durability of support. This introduction sets the stage for a concise but thorough examination of transformative shifts, regulatory and tariff influences, segmentation-level dynamics, regional differentiators, and actionable recommendations that help leaders prioritize investment and operational choices in this high-needs therapeutic area.
Clear and actionable description of how therapeutics, nutrition technology, and care models are converging to redefine treatment pathways for short bowel syndrome
The short bowel syndrome landscape is undergoing transformative shifts driven by therapeutic innovation, care delivery redesign, and greater emphasis on patient-centered outcomes. Pharmacologic agents that enhance intestinal adaptation and reduce parenteral dependence are moving from niche use toward broader integration with nutritional strategies, prompting adoption across specialty centers and outpatient settings. In parallel, improvements in enteral formula design and adjunctive products are addressing tolerability and micronutrient repletion, enabling more patients to transition from intensive parenteral support to mixed feeding regimens.
Care delivery is also shifting: multidisciplinary teams that combine gastroenterology, nutrition, surgery, and home health are replacing siloed approaches, which improves continuity and reduces complication rates. Technology is facilitating remote monitoring of parenteral therapy and early detection of catheter-related issues, while data-driven registries and real-world evidence initiatives are accelerating comparative effectiveness assessments. Finally, payer engagement is evolving to recognize long-term cost drivers and quality-of-life measures, which increases the importance of robust health economic modeling and patient-reported outcomes in market access strategies.
A pragmatic assessment of 2025 tariff impacts on supply chains, manufacturing economics, and access considerations within short bowel syndrome care delivery
The introduction of new tariff measures in the United States during 2025 has introduced a fresh set of operational considerations for manufacturers, suppliers, and care providers involved in short bowel syndrome management. Tariff-related cost pressures can influence sourcing decisions for raw materials used in enteral and parenteral solutions, affect the landed price of specialized compounds and medical devices, and create ripple effects across distributor agreements. Companies reliant on international supply chains may need to reassess supplier footprints and hedging strategies to sustain availability and manage margin volatility.
These trade measures also have implications for clinical supply continuity. Delays or increased costs associated with imported components can complicate manufacturing schedules and inventory planning for critical therapies and nutrition products. In response, organizations are exploring near-shoring, diversified supplier networks, and strategic inventory buffers to maintain service levels to home infusion providers and hospitals. From a commercial standpoint, tariff dynamics may require closer dialogue with payers and providers to communicate value propositions that justify pricing adjustments and to protect access for high-need patients. Overall, the cumulative impact of tariff shifts in 2025 underscores the need for integrated supply chain resilience and adaptable commercial models.
Detailed segmentation-driven insights explaining how treatment types, product classes, administration routes, care settings, age groups, and etiologies determine strategic priorities
Segmentation insights reveal how distinct therapeutic, product, administration, end-use, age, and etiology categories shape demand patterns and strategic priorities in short bowel syndrome. Based on Treatment Type, the market is organized across oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention, with oral supplementation further divided into dietary supplements and nutritional formulas; parenteral nutrition further broken down into customized PN and standard PN; pharmacological therapy further categorized into antibiotics, growth factors, and hormonal agents; and surgical intervention encompassing bowel transplantation and intestinal lengthening procedures, reflecting divergent clinical pathways and procurement channels. This treatment-focused segmentation illuminates how product development and clinical adoption must align with specific care objectives, whether reducing catheter dependence, managing bacterial overgrowth, or restoring intestinal length and function.
Based on Product Type, the landscape is characterized by adjunctive therapies, enteral formulas, pharmacologics, and PN solutions, where adjunctive therapies include probiotics and vitamins and minerals; enteral formulas span elemental, polymeric, and semi-elemental formulations; pharmacologics highlight agents such as teduglutide; and PN solutions include amino acid solutions, carbohydrate solutions, and lipid emulsions. Product-level segmentation highlights opportunities for incremental innovation around tolerability, nutrient composition, and stability, and it underscores distinct regulatory pathways for supplements versus prescription agents. Based on Route Of Administration, the dichotomy of intravenous and oral delivery influences patient adherence, monitoring needs, and home care capabilities. Based on End Use, the care setting distribution across home care facilities, hospitals, and specialty clinics affects procurement cycles, reimbursement touchpoints, and the nature of clinical partnerships. Based on Patient Age, segmentation among adult, geriatric, and pediatric populations reveals differing nutritional requirements, growth considerations, and risk profiles that must inform formulation and dosing strategies. Based on Etiology, distinctions among congenital conditions, Crohn disease, and mesenteric ischemia drive variability in disease progression and therapeutic sequencing, prompting tailored clinical pathways and targeted trial designs. Together, these segmentation lenses enable more granular go-to-market planning, clinical pathway alignment, and prioritized investment in product development and service delivery.
How regional care delivery models, regulatory diversity, and payer frameworks across key geographies shape access, adoption, and operational strategies for short bowel syndrome
Regional dynamics materially influence clinical practice patterns, regulatory environments, and commercial execution for short bowel syndrome, requiring tailored regional strategies. In the Americas, established home infusion networks, integrated specialty pharmacies, and consolidated hospital systems create opportunities for scalable distribution of parenteral solutions and coordinated patient monitoring programs, while also presenting reimbursement negotiation dynamics that must be navigated through robust value dossiers. Europe, Middle East & Africa presents heterogeneity across national health systems and regulatory pathways, which favors products and services that can demonstrate clear clinical benefit and cost-offsets; cross-border collaboration and regional centers of excellence facilitate access to advanced surgical options and registry participation. Asia-Pacific is notable for rapid healthcare infrastructure development, growing specialty care capacity, and opportunities to introduce innovations in enteral and parenteral nutrition as outpatient care expands, though market entry often requires localization of formulations, supply chain adaptations, and alignment with evolving reimbursement frameworks.
Across all regions, stakeholder engagement strategies should reflect local care delivery models, procurement conventions, and clinical practice guidelines. Partnerships with patient advocacy groups, investment in clinician education, and localized health economic narratives increase adoption potential. Moreover, region-specific supply chain and manufacturing considerations, including regulatory import requirements and quality assurance expectations, must be integrated into product launch and lifecycle planning to secure consistent patient access.
In-depth evaluation of how clinical pipelines, integrated service models, and supply chain resilience are defining competitive advantage among market participants
Leading companies active in short bowel syndrome are differentiating on multiple fronts: clinical development pipelines that extend therapeutic indications, integrated nutrition and drug solutions, and service models that combine product provision with patient support. Organizations are increasingly investing in translational research to expand indications for growth factors and hormonal agents, while also optimizing formulation science to improve stability and tolerability of enteral and parenteral products. Strategic collaborations between pharmaceutical developers, device manufacturers, and specialty nutrition providers are creating bundled offerings that can address both acute inpatient needs and chronic outpatient management.
Commercially, companies are enhancing patient support programs, digital monitoring capabilities, and home infusion partnerships to reduce complication rates and improve adherence. Mergers, acquisitions, and targeted licensing deals continue to be effective pathways to rapidly expand portfolios and geographic reach, particularly where manufacturing specialization or regulatory approvals are bottlenecks. Manufacturing excellence and supply chain diversification have become competitive differentiators, as reliable supply of PN components and specialty formulas is critical for provider relationships. Finally, robust evidence generation through registries, pragmatic trials, and real-world studies is central to building payer confidence and demonstrating long-term value, positioning leading firms to secure formulary placement and strengthen clinician adoption.
Actionable commercial, clinical evidence, and supply chain recommendations that enable leaders to reduce risk and accelerate adoption of short bowel syndrome solutions
Industry leaders should prioritize integrated strategies that align clinical evidence, supply chain resilience, and payer engagement to capture long-term value in short bowel syndrome. First, investments in clinical programs that generate outcomes relevant to both clinicians and payers-such as reduction in catheter-related infections, decreased parenteral dependence, and quality-of-life improvements-will create durable differentiation. Complementary real-world evidence initiatives and registries should be established early to support value narratives and reimbursement discussions.
Second, strengthening supply chain agility through supplier diversification, manufacturing redundancy, and localized capacity will mitigate tariff and trade-related risks while ensuring continuity for critical parenteral and enteral products. Third, develop bundled care propositions that integrate pharmacologic agents with nutrition solutions and patient support services to simplify procurement pathways for providers and payers. Fourth, tailor commercialization approaches by leveraging age- and etiology-specific clinical messaging and adapting formulations and dosing for pediatric, adult, and geriatric populations. Finally, invest in clinician education, telehealth-enabled monitoring, and home infusion partnerships to reduce complications, enhance patient adherence, and accelerate transitions from inpatient to outpatient care. These actions collectively improve patient outcomes and create defensible commercial positioning.
Transparent explanation of a mixed-methods research approach combining clinical evidence, expert interviews, and operational analysis to produce actionable strategic insights
This research combined a multi-method approach designed to triangulate clinical, commercial, and operational insights from diverse sources. We reviewed peer-reviewed clinical literature, guideline statements, and regulatory documents to map therapeutic mechanisms, safety considerations, and recommended practice patterns. Complementing the literature review, we analyzed clinical trial registries and patent landscapes to identify active development and innovation hotspots. Expert interviews with clinicians, nutrition specialists, hospital pharmacists, and home care providers provided grounded perspectives on clinical practice variation, barriers to adoption, and care pathway logistics.
Commercial and operational intelligence drew on public company disclosures, product labels, and manufacturing filings to assess supply chain and product composition characteristics. Where primary data were limited, qualitative synthesis and scenario analysis were used to explore potential impacts of trade and regulatory shifts. Analytical methods included cross-segmentation synthesis to align product attributes with care settings and patient populations, as well as thematic coding of expert interviews to identify recurring strategic priorities. Limitations of the methodology include variable granularity across geographies and evolving policy contexts; however, the mixed-methods design enhances robustness by combining clinical evidence with frontline stakeholder perspectives and operational data.
Concise synthesis highlighting the intersection of therapeutic innovation, operational resilience, and payer-aligned evidence needed to advance short bowel syndrome care
In conclusion, short bowel syndrome represents a therapeutic area where clinical innovation, nutrition science, and care delivery redesign intersect to create significant opportunities and responsibilities for stakeholders. Therapeutic advances are enabling meaningful reductions in parenteral dependence while improved formulas and home care models are enhancing patient autonomy. Nevertheless, external pressures such as trade dynamics and fragmented regional regulatory landscapes require proactive supply chain management and tailored market strategies. Decision-makers must prioritize evidence generation, integrated care models, and regional adaptation to ensure that innovations translate into sustained clinical benefit and reliable patient access.
Ultimately, success in this therapeutic domain will be defined by the ability to align clinical efficacy with operational excellence and payer-relevant value propositions. Organizations that invest in rigorous outcomes data, resilient manufacturing and distribution, and patient-centric service offerings will be best positioned to deliver durable solutions for individuals living with short bowel syndrome and to create commercially viable, ethically responsible models of care.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative overview of clinical burdens, multidisciplinary care demands, and commercial imperatives shaping short bowel syndrome treatment strategies
Short bowel syndrome presents a complex clinical and commercial landscape shaped by heterogeneous patient profiles, intricate nutritional requirements, and rapidly evolving therapeutic pathways. The condition creates sustained needs across medical nutrition, pharmacologic support, and procedural interventions, demanding coordinated care models that integrate specialty clinics, hospital systems, and home care services. Recent advances in pharmacology and surgical techniques are reshaping standards of care, while improvements in outpatient parenteral nutrition and home infusion services are changing how long-term support is delivered.
Clinicians and industry stakeholders face converging pressures: the imperative to improve patient quality of life, reduce catheter-related complications, and optimize nutrient absorption, alongside payer scrutiny and supply chain resilience requirements. Consequently, commercial strategies must balance clinical efficacy, ease of administration, and durability of support. This introduction sets the stage for a concise but thorough examination of transformative shifts, regulatory and tariff influences, segmentation-level dynamics, regional differentiators, and actionable recommendations that help leaders prioritize investment and operational choices in this high-needs therapeutic area.
Clear and actionable description of how therapeutics, nutrition technology, and care models are converging to redefine treatment pathways for short bowel syndrome
The short bowel syndrome landscape is undergoing transformative shifts driven by therapeutic innovation, care delivery redesign, and greater emphasis on patient-centered outcomes. Pharmacologic agents that enhance intestinal adaptation and reduce parenteral dependence are moving from niche use toward broader integration with nutritional strategies, prompting adoption across specialty centers and outpatient settings. In parallel, improvements in enteral formula design and adjunctive products are addressing tolerability and micronutrient repletion, enabling more patients to transition from intensive parenteral support to mixed feeding regimens.
Care delivery is also shifting: multidisciplinary teams that combine gastroenterology, nutrition, surgery, and home health are replacing siloed approaches, which improves continuity and reduces complication rates. Technology is facilitating remote monitoring of parenteral therapy and early detection of catheter-related issues, while data-driven registries and real-world evidence initiatives are accelerating comparative effectiveness assessments. Finally, payer engagement is evolving to recognize long-term cost drivers and quality-of-life measures, which increases the importance of robust health economic modeling and patient-reported outcomes in market access strategies.
A pragmatic assessment of 2025 tariff impacts on supply chains, manufacturing economics, and access considerations within short bowel syndrome care delivery
The introduction of new tariff measures in the United States during 2025 has introduced a fresh set of operational considerations for manufacturers, suppliers, and care providers involved in short bowel syndrome management. Tariff-related cost pressures can influence sourcing decisions for raw materials used in enteral and parenteral solutions, affect the landed price of specialized compounds and medical devices, and create ripple effects across distributor agreements. Companies reliant on international supply chains may need to reassess supplier footprints and hedging strategies to sustain availability and manage margin volatility.
These trade measures also have implications for clinical supply continuity. Delays or increased costs associated with imported components can complicate manufacturing schedules and inventory planning for critical therapies and nutrition products. In response, organizations are exploring near-shoring, diversified supplier networks, and strategic inventory buffers to maintain service levels to home infusion providers and hospitals. From a commercial standpoint, tariff dynamics may require closer dialogue with payers and providers to communicate value propositions that justify pricing adjustments and to protect access for high-need patients. Overall, the cumulative impact of tariff shifts in 2025 underscores the need for integrated supply chain resilience and adaptable commercial models.
Detailed segmentation-driven insights explaining how treatment types, product classes, administration routes, care settings, age groups, and etiologies determine strategic priorities
Segmentation insights reveal how distinct therapeutic, product, administration, end-use, age, and etiology categories shape demand patterns and strategic priorities in short bowel syndrome. Based on Treatment Type, the market is organized across oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention, with oral supplementation further divided into dietary supplements and nutritional formulas; parenteral nutrition further broken down into customized PN and standard PN; pharmacological therapy further categorized into antibiotics, growth factors, and hormonal agents; and surgical intervention encompassing bowel transplantation and intestinal lengthening procedures, reflecting divergent clinical pathways and procurement channels. This treatment-focused segmentation illuminates how product development and clinical adoption must align with specific care objectives, whether reducing catheter dependence, managing bacterial overgrowth, or restoring intestinal length and function.
Based on Product Type, the landscape is characterized by adjunctive therapies, enteral formulas, pharmacologics, and PN solutions, where adjunctive therapies include probiotics and vitamins and minerals; enteral formulas span elemental, polymeric, and semi-elemental formulations; pharmacologics highlight agents such as teduglutide; and PN solutions include amino acid solutions, carbohydrate solutions, and lipid emulsions. Product-level segmentation highlights opportunities for incremental innovation around tolerability, nutrient composition, and stability, and it underscores distinct regulatory pathways for supplements versus prescription agents. Based on Route Of Administration, the dichotomy of intravenous and oral delivery influences patient adherence, monitoring needs, and home care capabilities. Based on End Use, the care setting distribution across home care facilities, hospitals, and specialty clinics affects procurement cycles, reimbursement touchpoints, and the nature of clinical partnerships. Based on Patient Age, segmentation among adult, geriatric, and pediatric populations reveals differing nutritional requirements, growth considerations, and risk profiles that must inform formulation and dosing strategies. Based on Etiology, distinctions among congenital conditions, Crohn disease, and mesenteric ischemia drive variability in disease progression and therapeutic sequencing, prompting tailored clinical pathways and targeted trial designs. Together, these segmentation lenses enable more granular go-to-market planning, clinical pathway alignment, and prioritized investment in product development and service delivery.
How regional care delivery models, regulatory diversity, and payer frameworks across key geographies shape access, adoption, and operational strategies for short bowel syndrome
Regional dynamics materially influence clinical practice patterns, regulatory environments, and commercial execution for short bowel syndrome, requiring tailored regional strategies. In the Americas, established home infusion networks, integrated specialty pharmacies, and consolidated hospital systems create opportunities for scalable distribution of parenteral solutions and coordinated patient monitoring programs, while also presenting reimbursement negotiation dynamics that must be navigated through robust value dossiers. Europe, Middle East & Africa presents heterogeneity across national health systems and regulatory pathways, which favors products and services that can demonstrate clear clinical benefit and cost-offsets; cross-border collaboration and regional centers of excellence facilitate access to advanced surgical options and registry participation. Asia-Pacific is notable for rapid healthcare infrastructure development, growing specialty care capacity, and opportunities to introduce innovations in enteral and parenteral nutrition as outpatient care expands, though market entry often requires localization of formulations, supply chain adaptations, and alignment with evolving reimbursement frameworks.
Across all regions, stakeholder engagement strategies should reflect local care delivery models, procurement conventions, and clinical practice guidelines. Partnerships with patient advocacy groups, investment in clinician education, and localized health economic narratives increase adoption potential. Moreover, region-specific supply chain and manufacturing considerations, including regulatory import requirements and quality assurance expectations, must be integrated into product launch and lifecycle planning to secure consistent patient access.
In-depth evaluation of how clinical pipelines, integrated service models, and supply chain resilience are defining competitive advantage among market participants
Leading companies active in short bowel syndrome are differentiating on multiple fronts: clinical development pipelines that extend therapeutic indications, integrated nutrition and drug solutions, and service models that combine product provision with patient support. Organizations are increasingly investing in translational research to expand indications for growth factors and hormonal agents, while also optimizing formulation science to improve stability and tolerability of enteral and parenteral products. Strategic collaborations between pharmaceutical developers, device manufacturers, and specialty nutrition providers are creating bundled offerings that can address both acute inpatient needs and chronic outpatient management.
Commercially, companies are enhancing patient support programs, digital monitoring capabilities, and home infusion partnerships to reduce complication rates and improve adherence. Mergers, acquisitions, and targeted licensing deals continue to be effective pathways to rapidly expand portfolios and geographic reach, particularly where manufacturing specialization or regulatory approvals are bottlenecks. Manufacturing excellence and supply chain diversification have become competitive differentiators, as reliable supply of PN components and specialty formulas is critical for provider relationships. Finally, robust evidence generation through registries, pragmatic trials, and real-world studies is central to building payer confidence and demonstrating long-term value, positioning leading firms to secure formulary placement and strengthen clinician adoption.
Actionable commercial, clinical evidence, and supply chain recommendations that enable leaders to reduce risk and accelerate adoption of short bowel syndrome solutions
Industry leaders should prioritize integrated strategies that align clinical evidence, supply chain resilience, and payer engagement to capture long-term value in short bowel syndrome. First, investments in clinical programs that generate outcomes relevant to both clinicians and payers-such as reduction in catheter-related infections, decreased parenteral dependence, and quality-of-life improvements-will create durable differentiation. Complementary real-world evidence initiatives and registries should be established early to support value narratives and reimbursement discussions.
Second, strengthening supply chain agility through supplier diversification, manufacturing redundancy, and localized capacity will mitigate tariff and trade-related risks while ensuring continuity for critical parenteral and enteral products. Third, develop bundled care propositions that integrate pharmacologic agents with nutrition solutions and patient support services to simplify procurement pathways for providers and payers. Fourth, tailor commercialization approaches by leveraging age- and etiology-specific clinical messaging and adapting formulations and dosing for pediatric, adult, and geriatric populations. Finally, invest in clinician education, telehealth-enabled monitoring, and home infusion partnerships to reduce complications, enhance patient adherence, and accelerate transitions from inpatient to outpatient care. These actions collectively improve patient outcomes and create defensible commercial positioning.
Transparent explanation of a mixed-methods research approach combining clinical evidence, expert interviews, and operational analysis to produce actionable strategic insights
This research combined a multi-method approach designed to triangulate clinical, commercial, and operational insights from diverse sources. We reviewed peer-reviewed clinical literature, guideline statements, and regulatory documents to map therapeutic mechanisms, safety considerations, and recommended practice patterns. Complementing the literature review, we analyzed clinical trial registries and patent landscapes to identify active development and innovation hotspots. Expert interviews with clinicians, nutrition specialists, hospital pharmacists, and home care providers provided grounded perspectives on clinical practice variation, barriers to adoption, and care pathway logistics.
Commercial and operational intelligence drew on public company disclosures, product labels, and manufacturing filings to assess supply chain and product composition characteristics. Where primary data were limited, qualitative synthesis and scenario analysis were used to explore potential impacts of trade and regulatory shifts. Analytical methods included cross-segmentation synthesis to align product attributes with care settings and patient populations, as well as thematic coding of expert interviews to identify recurring strategic priorities. Limitations of the methodology include variable granularity across geographies and evolving policy contexts; however, the mixed-methods design enhances robustness by combining clinical evidence with frontline stakeholder perspectives and operational data.
Concise synthesis highlighting the intersection of therapeutic innovation, operational resilience, and payer-aligned evidence needed to advance short bowel syndrome care
In conclusion, short bowel syndrome represents a therapeutic area where clinical innovation, nutrition science, and care delivery redesign intersect to create significant opportunities and responsibilities for stakeholders. Therapeutic advances are enabling meaningful reductions in parenteral dependence while improved formulas and home care models are enhancing patient autonomy. Nevertheless, external pressures such as trade dynamics and fragmented regional regulatory landscapes require proactive supply chain management and tailored market strategies. Decision-makers must prioritize evidence generation, integrated care models, and regional adaptation to ensure that innovations translate into sustained clinical benefit and reliable patient access.
Ultimately, success in this therapeutic domain will be defined by the ability to align clinical efficacy with operational excellence and payer-relevant value propositions. Organizations that invest in rigorous outcomes data, resilient manufacturing and distribution, and patient-centric service offerings will be best positioned to deliver durable solutions for individuals living with short bowel syndrome and to create commercially viable, ethically responsible models of care.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emerging glucagon-like peptide-2 analog therapies expanding treatment options for short bowel syndrome
- 5.2. Advancements in intestinal lengthening surgical techniques improving patient outcomes in adults
- 5.3. Growing adoption of home parenteral nutrition delivery systems enhancing quality of life in SBS patients
- 5.4. Emerging regenerative medicine and tissue engineering approaches targeting intestinal mucosa restoration
- 5.5. Integration of telehealth services for nutritional management improving patient monitoring and adherence
- 5.6. Increasing focus on microbiome modulation therapies to reduce complications and support intestinal adaptation
- 5.7. Evolving reimbursement and pricing strategies impacting access to specialized SBS treatments across regions
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Short Bowel Syndrome Market, by Treatment Type
- 8.1. Oral Supplementation
- 8.1.1. Dietary Supplements
- 8.1.2. Nutritional Formulas
- 8.2. Parenteral Nutrition
- 8.2.1. Customized Pn
- 8.2.2. Standard Pn
- 8.3. Pharmacological Therapy
- 8.3.1. Antibiotics
- 8.3.2. Growth Factors
- 8.3.3. Hormonal Agents
- 8.4. Surgical Intervention
- 8.4.1. Bowel Transplantation
- 8.4.2. Intestinal Lengthening Procedures
- 9. Short Bowel Syndrome Market, by Product Type
- 9.1. Adjunctive Therapies
- 9.1.1. Probiotics
- 9.1.2. Vitamins And Minerals
- 9.2. Enteral Formulas
- 9.2.1. Elemental Formulas
- 9.2.2. Polymeric Formulas
- 9.2.3. Semi-elemental Formulas
- 9.3. Pharmacologics
- 9.3.1. Teduglutide
- 9.4. Pn Solutions
- 9.4.1. Amino Acid Solutions
- 9.4.2. Carbohydrate Solutions
- 9.4.3. Lipid Emulsions
- 10. Short Bowel Syndrome Market, by Route Of Administration
- 10.1. Intravenous
- 10.2. Oral
- 11. Short Bowel Syndrome Market, by Patient Age
- 11.1. Adult
- 11.2. Geriatric
- 11.3. Pediatric
- 12. Short Bowel Syndrome Market, by Etiology
- 12.1. Congenital Conditions
- 12.2. Crohn Disease
- 12.3. Mesenteric Ischemia
- 13. Short Bowel Syndrome Market, by End Use
- 13.1. Home Care Facilities
- 13.2. Hospitals
- 13.3. Specialty Clinics
- 14. Short Bowel Syndrome Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Short Bowel Syndrome Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Short Bowel Syndrome Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Ajinomoto Co., Inc.
- 17.3.2. Terumo Corporation
- 17.3.3. Becton, Dickinson and Company
- 17.3.4. ICU Medical, Inc.
- 17.3.5. Smiths Medical (Smiths Group plc)
- 17.3.6. Otsuka Holdings Co., Ltd.
- 17.3.7. Lonza Group AG
- 17.3.8. CordenPharma International AG
- 17.3.9. Gland Pharma Limited
- 17.3.10. Hikma Pharmaceuticals PLC
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
